uniQure (NASDAQ:QURE) Announces Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Posted by George Bondi on Nov 4th, 2026

uniQure (NASDAQ:QURE – Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.88) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.04, FiscalAI reports. uniQure had a negative return on equity of 111.96% and a negative net margin of 1,350.73%. The firm had revenue of $5.20 million during the quarter, compared to analyst estimates of $6.17 million.

Here are the key takeaways from uniQure’s conference call:

The FDA accepted uniQure’s BLA for AMT-130 and granted Priority Review, setting a target decision date of May 1, 2027; the U.K. regulator also validated the company’s marketing application. The FDA is tentatively planning an advisory committee discussion, but approval is not assured.
Management highlighted prior AMT-130 results showing a reported 75% slowing of disease progression on cUHDRS and 60% on Total Functional Capacity at 36 months versus a matched external control. The company also cited follow-up through 48 months, while noting the evidence comes from a small number of patients.
The planned confirmatory study will enroll about 200 patients, randomize them 2:1 to AMT-130 or standard of care, and assess TFC at 36 months; screening is expected to begin by year-end. UniQure says it is preparing to have the study well underway by a potential approval, while planning for possible control-arm dropouts and global recruitment.
Launch preparations are focused on specialist centers, with the company targeting more than 15 operational centers at launch but not yet specifying patient capacity. Management identified center readiness, institutional approvals and payer access as potential factors affecting how quickly patients could receive treatment.
Cash, cash equivalents and investments totaled $768.4 million at quarter-end, and management expects funding to last into 2030. SG&A increased year over year amid hiring and launch preparations; separately, the company expects updated AMT-260 epilepsy and AMT-191 Fabry data in the first half of 2027.

uniQure Stock Performance

QURE stock traded down $1.10 during midday trading on Wednesday, reaching $22.77. The company had a trading volume of 1,965,984 shares, compared to its average volume of 2,411,165. The firm has a market capitalization of $1.58 billion, a PE ratio of -5.72 and a beta of 1.14. The stock has a 50 day moving average price of $33.57 and a 200 day moving average price of $29.69. uniQure has a fifty-two week low of $8.73 and a fifty-two week high of $51.72. The company has a quick ratio of 10.01, a current ratio of 10.01 and a debt-to-equity ratio of 0.15.

Analyst Ratings Changes

A number of research analysts have commented on QURE shares. Wall Street Zen downgraded uniQure from a “hold” rating to a “sell” rating in a report on Saturday, September 5th. William Blair upgraded uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. The Goldman Sachs Group lowered their price target on uniQure from $46.00 to $31.00 and set a “neutral” rating for the company in a report on Wednesday, September 30th. Wells Fargo & Company reissued an “overweight” rating and set a $75.00 price target on shares of uniQure in a research report on Tuesday, September 29th. Finally, Weiss Ratings upgraded uniQure from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $56.83.

Check Out Our Latest Analysis on uniQure

uniQure Company Profile

(Get Free Report)

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.